germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...

Fundació Institut d'Investigació
en Ciències de la Salut
Germans Trias i Pujol
ANTIVIR THER 2006; 11(4):473‐482.
4,982
Guma M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, Lopez‐Botet M.
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in
aviremic HIV‐1‐positive patients.
J INFECT DIS 2006; 194(1):38‐41.
5,363
Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H.
Durable efficacy of tipranavir‐ritonavir in combination with an optimised background regimen of antiretroviral drugs for
treatment experienced HIV‐1‐infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi‐drug
resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open‐label trials.
Lancet 2006; 368(9534):466‐75
25,8
Hill A, Walmsley S, Clotet B, Molto J.
Analysis of genotypic and phenotypic clinical cut‐off levels for ritonavir‐boosted saquinavir.
HIV Med 2006; 7(2):67‐74.
2,674
Johnson VA, Brun‐Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.
Update of the drug resistance mutations in HIV‐1: Fall 2006.
TOP HIV MED 2006 Aug‐Sep;14(3):125‐30
Libois A, De Wit S, Poll B, Garcia F, Florence E, Del Rio A, Sanchez P, Negredo E, Vandenbruaene M, Gatell JM, Clumeck N.
HIV and Syphilis: When to Perform a Lumbar Puncture.
SEX TRANSM DIS 2006 Jul 19;
2,577
Lopez S, Negredo E, Garrabou G, Puig J, Ruiz L, Sanjurjo E, Ramos X, Infante AB, Casademont J, Cardellach F, Clotet B, Miro O.
Longitudinal study on mitochondrial effects of didanosine‐tenofovir combination.
AIDS RES HUM RETROV 2006; 22(1):33‐39.
2,513
Molto J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, DelaVarga M, Fumaz CR, Barbanoj MJ, Clotet B.
Variability in non‐nucleoside reverse transcriptase and protease inhibitor concentrations among HIV‐infected adults in routine
clinical practice.
BRIT J CLIN PHARMACO 2006; 62(5):560‐566.
2,718
Molto J, Ruiz L, Valle M, Martinez‐Picado J, Bonjoch A, Bravo I, Negredo E, Heilek‐Sneider GM, Clotet B.
Increased antiretroviral potency by the addition of enfuvirtide to a four‐drug regimen in antiretroviral‐naive, HIV‐infected
patients.
ANTIVIR THER 2006; 11(1):47‐51.
4,982
Negredo E, Bonjoch A, Clotet B.
Benefits and concerns of simplification strategies in HIV‐infected patients.
J ANTIMICROB CHEMOTH 2006; 58(2):235‐242.
3,891
Negredo E, Clotet B, Puig J, Perez‐Alvarez N, Ruiz L, Romeu J, Molto J, Rey‐Joly C, Blanco J.
The effect of atorvastatin treatment on HIV‐1‐infected patients interrupting antiretroviral therapy.
Aids 2006; 20(4):619‐621.
5,632
Negredo E, Higueras C, Adell X, Martinez JC, Martinez E, Puig J, Fumaz CR, Munoz‐Moreno JA, Perez‐Alvarez N, Videla S, Estany C,
Pàgina 175/177